

---

**TABLES**

---

1.1. Most Frequent Symptoms Among 3,558 Registry Participants . . . . .	2
3.1. Factors Leading to Individual Differences in Response to PB. . . . .	19
3.2. Reasons Extrapolation from Myasthenia to Normals May Not Be Valid . . . . .	20
3.3. Aging Half-Time of Nerve Agents . . . . .	33
3.4. Percentage of Population Within Target Area Exposed to Various Levels of Nerve Agent . . . . .	34
3.5. Effect of Therapy With and Without Pyridostigmine Pretreatment on Protective Ratios (PR) in Animals Exposed to Nerve Agents . . . . .	37
3.6. PB PRs for Soman Exposure (Guinea Pigs) . . . . .	42
3.7. Problems Leading to Medical Attention After PB Use in the PGW . . . . .	46
3.8. Symptom Frequency: Cross-Sectional Survey of 213 Israeli Soldiers . . . . .	47
5.1. Most Frequent Principal Diagnoses in PGW Registry Personnel . . . . .	58
5.2. Symptom Prevalence as Primary and Any Diagnosis . . . . .	59
5.3. Symptom Prevalence in Those with a Primary Diagnosis of Good Health . . . . .	59
5.4. Symptom Prevalence in Those Given a Diagnosis Other Than SSID. . . . .	60
5.5. Symptom Prevalence in Those Diagnosed with SSID . . . . .	60

5.6.	Registry Participation Predictors . . . . .	64
5.7.	Odds Ratios for CDC-Defined Persian Gulf War Illness, in Veterans from the PGW, Bosnia, or Gulf-Era Veterans Not Deployed to the Gulf . . . . .	66
8.1.	Effects of Different Esterases on PB Inactivation . . . . .	93
8.2.	Individual Variation in Esterases in Humans . . . . .	98
8.3.	PON Isoforms: Substrate Activities in Human Sera for Sarin, Soman, and PON . . . . .	99
9.1.	Sites of Action of PB: Possible Sites at Which Interaction May Occur with Other Drugs and Chemicals . . . . .	111
9.2.	Data Matrix: Binary Interactions Between PB and Selected Exposures . . . . .	112
10.1.	Bromide Blood Concentration and Toxicity . . . . .	136
11.1.	Complaints of PGW Veterans Enrolled in Persian Gulf Health Registry . . . . .	148
11.2.	Symptoms in MCS Patients . . . . .	149
11.3.	New Onset Intolerances Reported by Gulf War Veterans . . . . .	150
A.1.	Pyridostigmine Pharmacokinetic Data . . . . .	287
A.2.	Animal Data . . . . .	288
B.1.	Physiological Findings . . . . .	292
B.2.	Performance . . . . .	295
B.3.	Side Effects . . . . .	297